Why the study?
It remained unclear whether a prehospital rule-out strategy using the HEART score and a point-of-care troponin measurement in patients with suspected NSTE-ACS is cost-effective.
Does a prehospital rule-out strategy using the HEART score and a POC troponin measurement improve cost-effectiveness in low-risk patients suspected of NSTE-ACS?
Does a prehospital rule-out strategy using the HEART score and a POC troponin measurement improve cost-effectiveness in low-risk patients suspected of NSTE-ACS?
The ARTICA trial is designed to evaluate the cost-effectiveness of a prehospital rule-out strategy for NSTE-ACS using the HEART score and point-of-care troponin T.
Answers are grounded in this paper and cite their sources.
Establishes RCT framework for prehospital NSTE-ACS rule-out; leaves open cost-effectiveness until results reported.
INTRODUCTION: Because of the lack of prehospital protocols to rule out a non-ST-segment elevation acute coronary syndrome (NSTE-ACS), patients with chest pain are often transferred to the emergency department (ED) for thorough evaluation. However, in low-risk patients, an ACS is rarely found, resulting in unnecessary healthcare consumption. Using the HEART (History, ECG, Age, Risk factors and Troponin) score, low-risk patients are easily identified. When a point-of-care (POC) troponin measurement is included in the HEART score, an ACS can adequately be ruled out in low-risk patients in the prehospital setting. However, it remains unclear whether a prehospital rule-out strategy using the HEART score and a POC troponin measurement in patients with suspected NSTE-ACS is cost-effective. METHODS AND ANALYSIS: The ARTICA trial is a randomised trial in which the primary objective is to investigate the cost-effectiveness after 30 days of an early rule-out strategy for low-risk patients suspected of a NSTE-ACS, using a modified HEART score including a POC troponin T measurement. Patients are included by ambulance paramedics and 1:1 randomised for (1) presentation at the ED (control group) or (2) POC troponin T measurement (intervention group) and transfer of the care to the general practitioner in case of a low troponin T value. In total, 866 patients will be included. Follow-up will be performed after 30 days, 6 months and 12 months. ETHICS AND DISSEMINATION: This trial has been accepted by the Medical Research Ethics Committee region Arnhem-Nijmegen. The results of this trial will be disseminated in one main paper and in additional papers with subgroup analyses. TRIAL REGISTRATION NUMBER: Netherlands Trial Register (NL7148).
No takes yet. Share an insight, caveat, or question.
Aarts et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: